Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares BioPharma DiveIndustry executives can share their views on the national priority program at a June meeting.RegulatoryRead full story pharminent March 24, 2026 BioPharma Dive Industry executives can share their views on the national priority program at a June meeting. Regulatory Read full story Post navigation Previous: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit ManagersNext: Immutrin raises $87M to advance drug for progressive heart disease Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026